These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

250 related articles for article (PubMed ID: 29954776)

  • 1. STAG2 Is a Biomarker for Prediction of Recurrence and Progression in Papillary Non-Muscle-Invasive Bladder Cancer.
    Lelo A; Prip F; Harris BT; Solomon D; Berry DL; Chaldekas K; Kumar A; Simko J; Jensen JB; Bhattacharyya P; Mannion C; Kim JS; Philips G; Dyrskjøt L; Waldman T
    Clin Cancer Res; 2018 Sep; 24(17):4145-4153. PubMed ID: 29954776
    [No Abstract]   [Full Text] [Related]  

  • 2. STAG2 as a prognostic biomarker in low-grade non-muscle invasive bladder cancer.
    Taber A; Park Y; Lelo A; Prip F; Xiao J; Berry DL; Chaldekas K; Jensen JB; Philips G; Kim JS; Harris BT; Dyrskjøt L; Waldman T
    Urol Oncol; 2021 Jul; 39(7):438.e1-438.e9. PubMed ID: 33712344
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Identification of STAG2-Mutant Bladder Cancers by Immunohistochemistry.
    Park Y; Lelo A; Harris B; Berry DL; Chaldekas K; Kim JS; Waldman T
    Methods Mol Biol; 2023; 2684():145-151. PubMed ID: 37410232
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Next-generation Sequencing of Nonmuscle Invasive Bladder Cancer Reveals Potential Biomarkers and Rational Therapeutic Targets.
    Pietzak EJ; Bagrodia A; Cha EK; Drill EN; Iyer G; Isharwal S; Ostrovnaya I; Baez P; Li Q; Berger MF; Zehir A; Schultz N; Rosenberg JE; Bajorin DF; Dalbagni G; Al-Ahmadie H; Solit DB; Bochner BH
    Eur Urol; 2017 Dec; 72(6):952-959. PubMed ID: 28583311
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Unraveling UCA1 lncRNA prognostic utility in urothelial bladder cancer.
    Avgeris M; Tsilimantou A; Levis PK; Rampias T; Papadimitriou MA; Panoutsopoulou K; Stravodimos K; Scorilas A
    Carcinogenesis; 2019 Aug; 40(8):965-974. PubMed ID: 30815670
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Can re-cTURBT be useful in pT1HG disease as a risk indicator of recurrence and progression? A single centre experience.
    Giulianelli R; Gentile BC; Mirabile G; Albanesi L; Tariciotti P; Rizzo G; Buscarini M; Vermiglio M
    Arch Ital Urol Androl; 2017 Dec; 89(4):272-276. PubMed ID: 29473376
    [TBL] [Abstract][Full Text] [Related]  

  • 7. FOXM1 predicts disease progression in non-muscle invasive bladder cancer.
    Rinaldetti S; Wirtz R; Worst TS; Hartmann A; Breyer J; Dyrskjot L; Erben P
    J Cancer Res Clin Oncol; 2018 Sep; 144(9):1701-1709. PubMed ID: 29959570
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Ki-67 is an independent indicator in non-muscle invasive bladder cancer (NMIBC); combination of EORTC risk scores and Ki-67 expression could improve the risk stratification of NMIBC.
    Ding W; Gou Y; Sun C; Xia G; Wang H; Chen Z; Tan J; Xu K; Qiang D
    Urol Oncol; 2014 Jan; 32(1):42.e13-9. PubMed ID: 24360660
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The prognostic value of P-cadherin in non-muscle-invasive bladder cancer.
    Wang P; Lin SL; Zhang LH; Li Z; Liu Q; Gao JX; Liu DM; Bo JJ; Huang YR
    Eur J Surg Oncol; 2014 Mar; 40(3):255-9. PubMed ID: 24429027
    [TBL] [Abstract][Full Text] [Related]  

  • 10. RUNX3 methylation as a predictor for disease progression in patients with non-muscle-invasive bladder cancer.
    Yan C; Kim YW; Ha YS; Kim IY; Kim YJ; Yun SJ; Moon SK; Bae SC; Kim WJ
    J Surg Oncol; 2012 Mar; 105(4):425-30. PubMed ID: 22311819
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Expression signature defined by FOXM1-CCNB1 activation predicts disease recurrence in non-muscle-invasive bladder cancer.
    Kim SK; Roh YG; Park K; Kang TH; Kim WJ; Lee JS; Leem SH; Chu IS
    Clin Cancer Res; 2014 Jun; 20(12):3233-43. PubMed ID: 24714775
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Re: STAG2 is a Biomarker for Prediction of Recurrence and Progression in Papillary Non-Muscle-Invasive Bladder Cancer.
    Chang SS
    J Urol; 2020 Oct; 204(4):877. PubMed ID: 32716235
    [No Abstract]   [Full Text] [Related]  

  • 13. Clinical implications and prognostic values of topoisomerase-II alpha expression in primary non-muscle-invasive bladder cancer.
    Kim EJ; Lee YS; Kim YJ; Kim MJ; Ha YS; Jeong P; Lee OJ; Kim WJ
    Urology; 2010 Jun; 75(6):1516.e9-13. PubMed ID: 19913893
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Frequent truncating mutations of STAG2 in bladder cancer.
    Solomon DA; Kim JS; Bondaruk J; Shariat SF; Wang ZF; Elkahloun AG; Ozawa T; Gerard J; Zhuang D; Zhang S; Navai N; Siefker-Radtke A; Phillips JJ; Robinson BD; Rubin MA; Volkmer B; Hautmann R; Küfer R; Hogendoorn PC; Netto G; Theodorescu D; James CD; Czerniak B; Miettinen M; Waldman T
    Nat Genet; 2013 Dec; 45(12):1428-30. PubMed ID: 24121789
    [TBL] [Abstract][Full Text] [Related]  

  • 15. ΔNp63 transcript loss in bladder cancer constitutes an independent molecular predictor of TaT1 patients post-treatment relapse and progression.
    Papadimitriou MA; Avgeris M; Levis PK; Tokas T; Stravodimos K; Scorilas A
    J Cancer Res Clin Oncol; 2019 Dec; 145(12):3075-3087. PubMed ID: 31595333
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Stromal antigen 2 functions as a tumor suppressor in bladder cancer cells.
    Wang H; Zhong J; Wu C; Liu Y; Zhang J; Zou X; Chen Y; Su J; Yang G; Zhong Y; Tang A
    Oncol Rep; 2017 Aug; 38(2):917-925. PubMed ID: 28627627
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Molecular Markers Increase Precision of the European Association of Urology Non-Muscle-Invasive Bladder Cancer Progression Risk Groups.
    van Kessel KEM; van der Keur KA; Dyrskjøt L; Algaba F; Welvaart NYC; Beukers W; Segersten U; Keck B; Maurer T; Simic T; Horstmann M; Grimm MO; Hermann GG; Mogensen K; Hartmann A; Harving N; Petersen AC; Jensen JB; Junker K; Boormans JL; Real FX; Malats N; Malmström PU; Ørntoft TF; Zwarthoff EC
    Clin Cancer Res; 2018 Apr; 24(7):1586-1593. PubMed ID: 29367430
    [No Abstract]   [Full Text] [Related]  

  • 18. HMOX1 is an important prognostic indicator of nonmuscle invasive bladder cancer recurrence and progression.
    Yim MS; Ha YS; Kim IY; Yun SJ; Choi YH; Kim WJ
    J Urol; 2011 Feb; 185(2):701-5. PubMed ID: 21168882
    [TBL] [Abstract][Full Text] [Related]  

  • 19. STAG2 Protein Expression in Non-muscle-invasive Bladder Cancer: Associations with Sex, Genomic and Transcriptomic Changes, and Clinical Outcomes.
    Gordon NS; Humayun-Zakaria N; Goel A; Abbotts B; Zeegers MP; Cheng KK; James ND; Arnold R; Bryan RT; Ward DG
    Eur Urol Open Sci; 2022 Apr; 38():88-95. PubMed ID: 35495284
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Tumor expression of miR-34a-3p is an independent predictor of recurrence in non-muscle-invasive bladder cancer and promising additional factor to improve predictive value of EORTC nomogram.
    Juracek J; Stanik M; Vesela P; Radova L; Dolezel J; Svoboda M; Slaby O
    Urol Oncol; 2019 Mar; 37(3):184.e1-184.e7. PubMed ID: 30446443
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.